Quoin Pharmaceuticals, Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.2M
- Price
- $5.57
- % Change (Daily % change from the live per-ticker quote feed.)
- +11.62%
- Volume
- 72.1K
About
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Quick stats
Shares outstanding2.0M
Computed float1.5M
Float / shares72.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001671502
Websitehttps://quoinpharma.com
AI Summary
AI-generated1/15
standardbullishoperations update
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Quoin Pharmaceuticals received FDA clearance for the first-ever IND in Peeling Skin Syndrome, with a Phase 2/3 study expected to initiate in the second half of 2026.
The company also reported conditional FDA approval of the QYLEKI brand name for QRX003 in Netherton Syndrome and secured a U.S. patent allowance for a combination treatment.
Financially, Quoin holds $10.8 million in cash and marketable securities, which it believes will fund operations into 2027, while Q2 net loss widened to $5.4 million due to increased R&D spending.
Red flags
- Net loss widened to $5.4 million from $3.7 million in the prior year quarter
- Cash runway extends only into 2027